Patents Examined by Neil P Hammell
  • Patent number: 11401532
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 2, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11401380
    Abstract: Polyethylene glycol (PEG)-b-poly(?-amino ester) (PBAE) co-polymers (PEG-PBAE) and blends of PEG-PBAEs and PBAEs and their use for delivering drugs, genes, and other pharmaceutical or therapeutic agents safely and effectively to different sites in the body and to different cells, such as cancer cells, are disclosed.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: August 2, 2022
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jordan Green, Jayoung Kim, Stephany Tzeng
  • Patent number: 11371062
    Abstract: The present disclosure provides CasY proteins, nucleic acids encoding the CasY proteins, and modified host cells comprising the CasY proteins and/or nucleic acids encoding same. CasY proteins are useful in a variety of applications, which are provided. The present disclosure provides CasY guide RNAs that bind to and provide sequence specificity to the CasY proteins, nucleic acids encoding the CasY guide RNAs, and modified host cells comprising the CasY guide RNAs and/or nucleic acids encoding same. CasY guide RNAs are useful in a variety of applications, which are provided. The present disclosure provides methods of identifying a CRISPR RNA-guided endonuclease.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 28, 2022
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Jillian F. Banfield, David Burstein, Lucas Benjamin Harrington
  • Patent number: 11371069
    Abstract: Disclosed herein are methods for improving ethanol production from biomass sources by blocking cellulose from binding to lignin.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: June 28, 2022
    Assignee: Purdue Research Foundation
    Inventors: Michael Ralph Ladisch, Young Mi Kim
  • Patent number: 11371048
    Abstract: The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product.
    Type: Grant
    Filed: September 11, 2016
    Date of Patent: June 28, 2022
    Assignee: ABSCI LLC
    Inventors: Sean McClain, Mark Valasek, Philip Barish, Jeremy Minshull
  • Patent number: 11332761
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 17, 2022
    Assignees: The Regenis of Wie University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11326209
    Abstract: The present invention relates to a cell based genomic Recorded Accumulative Memory (geRAM) system (also referred to herein as Genomically Encoded Memory (GEM)) for recoding data (i.e., changes in nucleic acid sequences in cellular DNA in response to physical and/or chemical signal(s)) from the cellular environment.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: May 10, 2022
    Assignees: Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research
    Inventors: Joseph M. Jacobson, Noah Jakimo, Naama Kanarek, David Sabatini
  • Patent number: 11293034
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: April 5, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11293022
    Abstract: This invention pertains to single-stranded carrier nucleic acids and their methods of use for enhancing genome editing ribonucleoprotein complex transfection into cells and the resulting enhancement of CRISPR editing on the target DNA within those cells, as well as introduction of chemical modifications which reduce the integration of the single-stranded carrier nucleic acids at double-stranded breaks.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: April 5, 2022
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Rolf Turk, Mark A. Behlke, Chris Vinci
  • Patent number: 11286468
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 29, 2022
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Patent number: 11279926
    Abstract: The present disclosure provides methods, kits, and compositions for generating DNA molecules encoding CRISPR/Cas guide RNAs (e.g., Cas9 single guide RNAs or Cas9 targeter RNAs). A library of such DNA molecules can be generated from any DNA source. The methods include a step of contacting target DNA with one or more DNA endonucleases that specifically bind to and cleave within a recognition sequence that includes a PAM sequence, to generate a plurality of cleavage fragments, to which a DNA adapter can be attached. A distal-cleaving DNA endonuclease can be used that specifically binds to a recognition sequence in the DNA adapter and cleaves at a site within the attached DNA cleavage fragments to generate a library of CRISPR/Cas guide sequences. After removal of all or a portion of the DNA adapter, a constant region of a guide RNA can be attached to generate DNA molecules encoding CRISPR/Cas guide RNAs.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: March 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Andrew B. Lane, Rebecca Heald
  • Patent number: 11274305
    Abstract: Methods and kits for excising HIV-1 DNA in vivo are provided, which employ Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-Associated (cas) proteins. Vectors harboring nucleic acids encoding one or more guide RNA, wherein said guide RNA hybridizes with a target HIV-1 DNA are also provided.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: March 15, 2022
    Assignees: TRUSTEES OF DARTMOUTH COLLEGE, United States Government as Represented by The Department of Veterans Affairs
    Inventors: Alexandra L. Howell, Susan K. Eszterhas
  • Patent number: 11274318
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: March 15, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11268082
    Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cpf1 or variants thereof, and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a napDNAbp (e.g., CasX, CasY, Cpf1, C2c1, C2c2, C2C3, and Argonaute) and nucleic acid editing proteins or domains, are provided.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 8, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Alexis Christine Komor, Liwei Chen, Holly A. Rees
  • Patent number: 11261470
    Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti FcRn antibodies and proteins made by the methods described herein.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Philip Jonathan Bassett, David Paul Humphreys, Pareshkumar Manjibhai Patel
  • Patent number: 11254933
    Abstract: Methods, compositions, and kits are provided for CRISPR/Cas mediated transcriptional modulation.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: February 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Luke A Gilbert, Max Horlbeck, Martin Kampmann, Lei S Qi, Jonathan S Weissman
  • Patent number: 11254918
    Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 22, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Novome Biotechnolooies, Inc.
    Inventors: Justin L. Sonnenburg, Weston R. Whitaker, Elizabeth Stanley, William C. DeLoache
  • Patent number: 11249084
    Abstract: This document relates to materials and methods involved in assessing inflammatory bowel disease patients at risk for developing cancer. For example, materials and methods for monitoring colorectal cancer risk in ulcerative colitis patients are provided.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: February 15, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Megan Garrity-Park, Thomas C. Smyrk, Edward V. Loftus, Jr., William J. Sandborn
  • Patent number: 11242543
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: February 8, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11208638
    Abstract: The present disclosure provides a Cas9 heterodimer, as well as nucleic acids encoding the Cas9 heterodimer, and host cells comprising the nucleic acids. The present disclosure provides a system that includes a Cas9 heterodimer of the present disclosure and at least one of: a Cas9 guide RNA, and a dimerizing agent. A Cas9 heterodimer of the present disclosure is useful in a wide variety of applications, which are also provided.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: December 28, 2021
    Assignee: The Regents of the University of California
    Inventors: Samuel H. Sternberg, Jennifer A. Doudna, Addison V. Wright